Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK's 10-valent PCV or Pfizer's 13-valent PCV in the Slovak Republic.

Trial Profile

Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK's 10-valent PCV or Pfizer's 13-valent PCV in the Slovak Republic.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms PCV-MIXED-SCHEDULE
  • Most Recent Events

    • 27 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top